Itacitinib

Generic Name
Itacitinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C26H23F4N9O
CAS Number
1334298-90-6
Unique Ingredient Identifier
19J3781LPM
Background

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Associated Conditions
-
Associated Therapies
-

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2019-06-07
Last Posted Date
2023-11-14
Lead Sponsor
Incyte Corporation
Target Recruit Count
23
Registration Number
NCT03978637
Locations
πŸ‡ΊπŸ‡Έ

Brigham and Women'S Faulkner Hospitals Inc, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Temple University Department of Thoracic Medicine and Surgery, Philadelphia, Pennsylvania, United States

πŸ‡§πŸ‡ͺ

Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium

and more 6 locations

Itacitinib for Low Risk GVHD

First Posted Date
2019-02-19
Last Posted Date
2023-02-06
Lead Sponsor
John Levine
Target Recruit Count
70
Registration Number
NCT03846479
Locations
πŸ‡ΊπŸ‡Έ

The Mount Sinai Hospital, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Ohio State University, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 11 locations

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

First Posted Date
2018-10-26
Last Posted Date
2023-02-21
Lead Sponsor
Incyte Corporation
Target Recruit Count
2
Registration Number
NCT03721965
Locations
πŸ‡ΊπŸ‡Έ

University of Minnesota Medical Center, Minneapolis, Minnesota, United States

πŸ‡ΊπŸ‡Έ

Duke University Medical Center, Durham, North Carolina, United States

πŸ‡ΊπŸ‡Έ

University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States

and more 33 locations

Itacitinib + Everolimus in Hodgkin Lymphoma

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-10-05
Last Posted Date
2024-11-14
Lead Sponsor
University of Pennsylvania
Target Recruit Count
23
Registration Number
NCT03697408
Locations
πŸ‡ΊπŸ‡Έ

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

First Posted Date
2018-08-13
Last Posted Date
2019-12-06
Lead Sponsor
Incyte Corporation
Registration Number
NCT03627052

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

First Posted Date
2018-07-12
Last Posted Date
2024-01-24
Lead Sponsor
Incyte Corporation
Target Recruit Count
155
Registration Number
NCT03584516
Locations
πŸ‡ΊπŸ‡Έ

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Loyola University Medical Center, Maywood, Illinois, United States

πŸ‡ΊπŸ‡Έ

Jefferson University Hospitals, Philadelphia, Pennsylvania, United States

and more 130 locations

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

First Posted Date
2018-04-13
Last Posted Date
2020-03-03
Lead Sponsor
Incyte Corporation
Target Recruit Count
14
Registration Number
NCT03497273
Locations
πŸ‡―πŸ‡΅

JA-Aichi Anjo Kosei Hospital, Anjo-Shi, Aichi, Japan

πŸ‡―πŸ‡΅

Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan

πŸ‡―πŸ‡΅

Kanagawa Cancer Center, Yokohama-shi, Kanagawa-Ken, Japan

and more 14 locations

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

First Posted Date
2018-02-07
Last Posted Date
2023-09-13
Lead Sponsor
University of Pennsylvania
Target Recruit Count
23
Registration Number
NCT03425006
Locations
πŸ‡ΊπŸ‡Έ

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Β© Copyright 2024. All Rights Reserved by MedPath